These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 28428285)

  • 1. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
    Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between androgen receptor expression and surrogate molecular subtypes in invasive breast carcinoma].
    Sun XJ; Zuo K; Tang SX; Lu HF; Shui RH; Yu BH; Xu XL; Cheng YF; Tu XY; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2017 Jul; 46(7):476-480. PubMed ID: 28728221
    [No Abstract]   [Full Text] [Related]  

  • 4. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
    Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y; Lu S; Zeng W; Xie S; Xiao S
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
    Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma.
    Stolnicu S; Tunde C; Cadar A; Boros M
    Pol J Pathol; 2020; 71(1):62-65. PubMed ID: 32429656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
    Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
    Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH; Shaaban HM
    Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
    Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
    Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
    Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
    Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Male breast carcinoma: a clinicopathological and immunohistochemical characterization study.
    Zhou R; Yu L; Zhou S; Bi R; Shui R; Yu B; Lu H; Cai X; Yang W
    Int J Clin Exp Pathol; 2014; 7(10):6852-61. PubMed ID: 25400768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM; Mentrikoski MJ; Wick MR
    Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
    Boto A; Harigopal M
    Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
    Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
    Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.